ONCORUS INC (ONCR)       0.6118  -0.01 (-1.34%)

0.6118  -0.01 (-1.34%)

US68236R1032 - Common Stock - After market: 0.6118 0 (0%)

News Image
an hour ago - Oncorus, Inc.

Oncorus Announces Portfolio Reprioritization to Focus on IV-Administered, Self-Amplifying RNA Medicines for Patients with Cancer

Company now focused on the development of ONCR-021, Oncorus’ lead self-amplifying RNA product candidate for non-small cell lung and other cancers; program...

News Image
7 days ago - Oncorus, Inc.

Oncorus to Participate in Upcoming Investor Conferences

ANDOVER, Mass., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to...

News Image
12 days ago - Oncorus, Inc.

Oncorus Presents Preclinical Data Supporting ONCR-719, an armed HSV-1 Vector engineered to use the Epidermal Growth Factor Receptor (EGFR/EGFRvIII) for viral entry in Glioblastoma, at the 2022 Society for Neuro-Oncology Annual Meeting

ONCR-719 is uniquely engineered to use the Epidermal Growth Factor Receptor (EGFR/EGFRvIII) for viral entry, which is highly expressed in glioblastoma...

News Image
a month ago - Oncorus, Inc.

Oncorus Reports Third Quarter 2022 Financial Results and Provides Business Updates

Additional clinical data from ONCR-177 surface lesion monotherapy and combination expansion cohorts expected in the fourth quarter of 2022On track to...

News Image
2 months ago - Oncorus, Inc.

Oncorus Announces Publication in Nature Communications Highlighting the Development of its Intravenously Administered Synthetic vRNA/LNP Platform for the Treatment of Cancer

New preclinical results support self-amplifying vRNA/LNP immunotherapy platform and ongoing IND-enabling studies of ONCR-021...

News Image
2 months ago - Oncorus, Inc.

Oncorus Announces Publication in Nature Communications Highlighting the Development of its Intravenously Administered Synthetic vRNA/LNP Platform for the Treatment of Cancer

New preclinical results support self-amplifying vRNA/LNP immunotherapy platform and ongoing IND-enabling studies of ONCR-021

News Image
2 months ago - Oncorus, Inc.

Oncorus to Present at Chardan’s 6th Annual Genetic Medicines Conference

ANDOVER, Mass., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to...

News Image
3 months ago - Oncorus, Inc.

Oncorus to Present at the H.C. Wainwright 24th Annual Global Investment Conference

CAMBRIDGE, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to...

News Image
4 months ago - Oncorus, Inc.

Oncorus Reports Second Quarter 2022 Financial Results and Provides Business Updates

Additional clinical data from ONCR-177 surface lesion monotherapy and combination expansion cohorts expected in second half of 2022Company remains on track...

News Image
5 months ago - Oncorus, Inc.

Oncorus Appoints Douglas Fambrough to Board of Directors

-Former CEO of Dicerna brings deep expertise in RNA research, drug development, business development and financing- CAMBRIDGE, Mass., June 23, 2022 ...

News Image
6 months ago - Market News Video

Interesting ONCR Call Options For July 15th

News Image
6 months ago - Oncorus, Inc.

Oncorus to Present at the Jefferies Global Healthcare Conference

CAMBRIDGE, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to...

News Image
7 months ago - Oncorus, Inc.

Oncorus to Present at the H.C. Wainwright Global Investment Conference

CAMBRIDGE, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to...

News Image
7 months ago - Oncorus, Inc.

Oncorus Reports First Quarter 2022 Financial Results and Provides Business Updates

Additional clinical data from ONCR-177 surface lesion monotherapy expansion and combination expansion cohorts expected in second half of 2022Preclinical...

News Image
8 months ago - Oncorus, Inc.

Oncorus Presents Preclinical Data on ONCR-021 and ONCR-788 Supporting Selectively Self-Amplifying vRNA Immunotherapy Platform at AACR Annual Meeting

– ONCR-021 and ONCR-788 demonstrate robust preclinical anti-tumor efficacy following IV-administration – – vRNA Immunotherapy Platform has the potential...

News Image
8 months ago - InvestorPlace

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

Good morning, investor! It's time to start off another busy day of trading with the biggest pre-market stock movers for Tuesday!

News Image
8 months ago - Oncorus, Inc.

Oncorus Announces Debt Capital Facility with K2 HealthVentures with $20 Million Funded at Closing, Relocation of Corporate Headquarters and Extension of Cash Runway

-Multiple tranche debt financing agreement provides Oncorus with access to up to $45 million- -Use of proceeds intended to support completion of a...